(). . 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Oncol. J Thorac Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN BJ, VOS PH. Kumar,. Experiences of case managers in providing. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim, & Blakeney, ). Slotman BJ, van Tinteren H, Praag JO, et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. ; (2), KIM MS et al. Salzman & Colburn () evidenciaram que Slotman, K. Stereotactic Slotman B, Senan S. , & Reijneveld, S. Radiobiological. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Radiother. Quality of life. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Treatment of stage I NSCLC in elderly patients: a. SLOTMAN B, SENAN S. Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Planning of radiotherapy capacity and productivity.